<DOC>
	<DOCNO>NCT01568008</DOCNO>
	<brief_summary>This observational study patient POAG OHT collect data use Lumigan® 0.01 % ( bimatoprost 0.01 % ophthalmic solution ) routine clinical setting . Patients see baseline follow-up visit approximately 8-12 week baseline , per normal clinical practice .</brief_summary>
	<brief_title>Observational Study Lumigan® 0.01 % Treatment Primary Open Angle Glaucoma ( POAG ) Ocular Hypertension ( OHT )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis POAG OHT Prescribed Lumigan® 0.01 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>